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Abstract S-Farnesyl-thioacetic acid (FTA), a competitive
inhibitor of isoprenylated protein methyltransferase, potently
suppressed the growth of HL-60 cells and induced apoptosis, as
evidenced by the development of increased annexin-V binding,
decreased binding of DNA dyes and internucleosomal DNA
degradation. FTA did not impair the membrane association of
ras proteins, conversely, it brought about a decrease in the
proportion of ras present in the cytosolic fraction. Farnesylated
molecules which are weak inhibitors of the methyltransferase
also induced DNA laddering and reduced the proportion of
cytosolic ras. These findings suggest that neither inhibition of
isoprenylated protein methylation nor impairment of ras
membrane association are essential for apoptosis induced by
farnesylcysteine analogs.
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1. Introduction
G proteins (Gp) are posttranslationally modi¢ed by isopre-
nylation and methylation. While isoprenylation is essential for
Gp membrane association and function, methylation is re-
quired for full activity (see [1] and [2] for review). Gp meth-
ylation is carried out by speci¢c methyltransferases [3,4],
which recognize the isoprenylated carboxyl terminal cysteine
[5,6]. Extensive structure-activity studies on the partially pu-
ri¢ed isoprenylated protein methyltransferase (PPMTase)
from bovine retinal rod outer segments have allowed to obtain
a battery of small molecule analogs of the isoprenylated Gp
C-terminus, which behave as substrates and/or inhibitors of
the enzyme [7]. Among these molecules, N-acetyl-S-farnesyl-L-
cysteine (L-AFC) is a good substrate for retinal PPMTase,
with a Km of approximately 20 WM [6], while the steroisomer
D-AFC is a poorer substrate, with a Km of 70 WM [7]. An-
other compound, farnesyl-thioacetic acid (FTA), is a potent
competitive inhibitor both of L-AFC methylation, with a Ki
of 5 WM, and of the methylation of the endogenous retinal
isoprenylated proteins in in vitro assays [6]. L-AFC has been
widely used as a competitive inhibitor of PPMTase to explore
the importance of isoprenylated protein carboxyl methylation
in signal transduction processes in numerous experimental
systems. The e¡ects encountered evidence an impairment of
various cellular functions elicited by the activation of G pro-
tein-coupled receptors, including the release of superoxide
anion induced by formyl-peptide in human neutrophils [8,9],
agonist-receptor-mediated platelet aggregation [10] and the
chemotactic responses of mouse peritoneal macrophages
[11], while other signal transduction pathways, like those elic-
ited by calcium ionophores or by direct activation of protein
kinase C with phorbol esters, seem una¡ected [8^10]. In spite
of the selectivity that analogs of AFC exhibit for Gp-depend-
ent processes, some of their biological e¡ects appear to be
independent from their behavior as methylation inhibitors.
On one hand, L-AFC has been reported to interfere with
receptor-mediated Gp activation by a mechanism independent
of the inhibition of Gp methylation [12]. On the other hand,
farnesylcysteine analogs have been shown to exert either pos-
itive or negative e¡ects on neutrophil activation, measured as
superoxide release, in a way not related to the blockade of
PPMTase activity [9]. In addition, it has been shown that
farnesylated molecules which are not inhibitors of the meth-
yltransferase are able to block thrombin-induced platelet ag-
gregation [13]. Accumulating evidence suggests that the iso-
prenoid moiety of certain proteins could play an important
role in protein^protein interactions [14^17].
Interestingly, an isoprenoid acceptor structure has been re-
cently identi¢ed in the guanosine diphosphate (GDP)-dissoci-
ation inhibitor of rho proteins, rho-GDI [18]. These observa-
tions raise the possibility that farnesylated compounds may
exert their diverse biological e¡ects through the interaction
with intracellular targets not yet identi¢ed. It has been re-
cently reported that certain farnesyl-based inhibitors of
PPMTase can inhibit ras-dependent cell growth [19]. In this
study we have explored the e¡ect of several farnesylated mol-
ecules, with widely divergent activities towards PPMTase, on
the growth and viability of human leukemic HL-60 cells.
2. Materials and methods
2.1. Materials
N-Acetyl-S-farnesyl-L-cysteine (L-AFC), N-acetyl-S-farnesyl-D-cys-
teine (D-AFC) and farnesyl-S-thioacetic acid (FTA) were synthesized
as previously described [6,7]. The synthesis of farnesoic acid (FA),
farnesyl-phosphate methyl ester (FPMe) and farnesyl-phosphate di-
methyl ester (FPMe2) will be reported in detail elsewhere. Pan-Ras-
10 (Ab-3) monoclonal antibody was from Oncogene Science (Union-
dale, NY). Mouse monoclonal anti-calmodulin antibody was from
Zymed Laboratories, Inc. (San Francisco, CA), and peroxidase-con-
jugated anti-mouse immunoglobulins were from Dako (Glostrup,
Denmark). Annexin V- FITC and RNase A were from Boehringer
Mannheim. S-Adenosyl-methyl-[3H]methionine (80 Ci/mmol) and
Amplify were from Amersham (Buckinghamshire, UK). All other
reagents were of the highest purity available from Sigma Co. (St.
Louis, MO).
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2.2. Cell culture
Human promyelocytic HL-60 leukemic cells were grown in RPMI
1640 supplemented with 10% (v/v) heat-inactivated fetal calf serum,
2 mM glutamine, penicillin (100 U/ml) and gentamycin (24 Wg/ml), at
37‡C under 5% CO2 in a humidi¢ed atmosphere. For experiments,
cells were incubated in serum-free medium supplemented with insulin
(5 Wg/ml) and transferrin (5 Wg/ml) [20], at a density of 2.5U105 cells/
ml. Farnesylcysteine analogs were added in 0.1% (v/v) dimethyl sulf-
oxide (DMSO), ¢nal concentration. Control cells received an equiv-
alent amount of DMSO. This DMSO concentration did not induce
cell di¡erentiation or apoptosis. Cell viability was evaluated by trypan
blue dye exclusion.
2.3. Cell cycle analysis
Approximately 106 cells per experimental condition were harvested,
washed with phosphate bu¡ered saline (PBS) and resuspended in
250 Wl of the same bu¡er. Cell suspensions were incubated for 30
min at r.t. in the presence of 0.1% Nonidet P-40, 50 Wg/ml propidium
iodide and 50 Wg/ml RNase ¢nal concentrations, and the DNA con-
tent per cell was estimated by £ow cytometry as previously described
[21].
2.4. Analysis of annexin V-FITC binding
Approximately 5U105 cells per experimental condition were har-
vested, washed with phosphate bu¡ered saline (PBS) and resuspended
in 150 Wl of HEPES bu¡er (10 mM HEPES-Na, pH 7.4, 150 mM
NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2). Cells were incu-
bated for 15 min at 37‡C in the presence of 2 Wg/ml of annexin V-
FITC, washed twice with HEPES bu¡er and resuspended in 400 Wl of
the same bu¡er. To distinguish cells which had lost membrane integ-
rity, propidium iodide was added to a ¢nal concentration of 50 Wg/ml
before £ow cytometry analysis [22].
2.5. DNA fragmentation
Fragmented DNA was obtained basically as described [23]. Brie£y,
approximately 4U106 cells from each experimental condition were
lysed by incubation in 10 mM Tris-HCl, pH 7.5, 1 mM EDTA,
0.2% Triton X-100, for 30 min at 4‡C. Cell organelles were removed
by centrifugation at 12 000Ug for 20 min and the fragmented DNA
present in the supernatant was precipitated as described [23], and
resuspended in 50 Wl of 10 mM Tris-HCl, pH 8.0, 1 mM EDTA.
Aliquots (5 Wl) were analyzed by electrophoresis on 1% agarose gels.
2.6. SDS-PAGE and immunoblotting
For SDS-PAGE, HL-60 cells were homogenized by forced passes
through a 261=2 G needle in 10 mM Tris, pH 7.5, 0.1 mM EDTA,
0.1 mM EGTA, 0.1 mM L-mercaptoethanol, containing 2 Wg/ml of
each of the protease inhibitors leupeptin, aprotinin and trypsin inhib-
itor. S100 (cytosol) and P100 (membrane) fractions were obtained by
centrifugation at 200 000Ug for 30 min in a Beckman TLA100 rotor.
Aliquots from each fraction containing 20 Wg of protein were electro-
phoresed on 15% polyacrylamide gels and transferred to Immobilon-P
membranes (Millipore, Bedford, MA). Even loading and transfer were
ensured by Ponceau staining. Blots were incubated with pan-Ras-10
antibody (1:500 dilution) and the proteins of interest were visualized
using an ECL detection system from Amersham. In some experi-
ments, blots were re-probed with anti-calmodulin antibody (1:10 000
dilution).
2.7. Methylation of HL-60 cell proteins in vitro
The activity of PPMTase towards endogenous substrates was moni-
tored in vitro essentially as described [9]. Brie£y, cell extracts (2 mg of
total protein/ml) were incubated with 14 WCi of [3H]-S-adenosylme-
thionine ([3H]SAM) (1.75 WM; 80 Ci/mmol) in 100 mM HEPES, pH
7.4, 100 mM NaCl, 4 mM MgCl2, 1 mM DTT at 37‡C for 30 min, in
the absence or presence of analogs at 50 WM. For electrophoresis,
samples were precipitated by the addition of 0.1% (w/v) deoxycholate
and 10% (w/v) trichloroacetic acid and centrifuged at 14 000Ug for
10 min. The protein pellets were solubilized in sample bu¡er contain-
ing 5% SDS, boiled for 5 min and run on 12.5% polyacrylamide gels.
Gels were treated with Amplify (Amersham), dried and exposed to
¢lm at 380‡C for 3 days.
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Fig. 1. E¡ect of FTA on the growth and cell cycle distribution of HL-60 cells. A: HL-60 cells were grown in the presence of the indicated con-
centrations of FTA. At the indicated time points, viable cells were counted on a hemocytometer chamber. B: Cell cycle analysis of HL-60 cells
treated with the indicated concentrations of FTA for 8 h. The proportion of cells in the sub-G1 peak (arrowheads) is given. C: Binding of an-
nexin V-FITC to FTA-treated cells, vs. loss of plasma membrane integrity, as assessed by propidium iodide uptake. The proportion of cells
within each quadrant is given in inserts. Results shown are representative of three independent experiments.
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3. Results
3.1. E¡ect of FTA on the growth and cell cycle distribution of
HL-60 cells
Incubation of HL-60 cells in the presence of FTA inhibited
cell growth in a dose-dependent manner (Fig. 1A). Inhibition
was complete at 5 WM FTA. This e¡ect was accompanied by a
loss of cell viability, as well as by morphological alterations
including cell shrinking (results not shown). The study of the
cell cycle distribution of HL-60 cells treated with FTA re-
vealed the dose-dependent appearance of a distinct population
of cells with a decreased binding of the DNA-binding dye, a
characteristic of early apoptotic cells [24], which integrate the
so-called sub-G1 peak (Fig. 1B). The induction of apoptosis
by FTA was also suggested by the appearance of a population
of cells with increased annexin-V binding (Fig. 1C), an indi-
cation of the exposure of negatively charged phospholipids to
the outer surface of the plasma membrane [22]. This cell pop-
ulation maintained a low (close to background) staining with
propidium iodide, which is indicative of membrane integrity,
and therefore represents early apoptotic cells. In addition,
analysis of DNA from FTA-treated cells showed an internu-
cleosomal degradation which gave rise to the DNA laddering
pattern characteristic of some apoptotic processes (see Fig.
4A).
3.2. E¡ect of FTA on methyltransferase activity in HL-60 cell
extracts
The activity of protein methyltransferase towards the en-
dogenous substrates was assessed by incubating HL-60 cell
extracts in the presence of [3H]SAM. This resulted in the in-
corporation of radioactivity in several polypeptides with ap-
parent molecular masses of 14^17, 20^23, 32, 40 and 46 kDa
(Fig. 2A). The most prominently methylated polypeptides
were in the 20^23 kDa range, where small Gp are known to
occur. FTA inhibited protein methylation in HL-60 extracts.
This inhibition was more evident for the 20^23 kDa group of
polypeptides (Fig. 2A). Half maximal inhibition of the meth-
ylation of this group of proteins was achieved with 30 WM
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Fig. 2. E¡ect of FTA on the methylation of endogenous substrates
in extracts of HL-60 cells. Protein methylation in HL-60 cell ex-
tracts was performed by incubation with [3H]SAM in the absence
or presence of FTA at the indicated concentrations. The experiment
was repeated three times with di¡erent preparations of cells. A rep-
resentative autoradiograph is shown in A and the densitometric
quantitation of the radioactivity incorporated in the groups of poly-
peptides marked in A is shown in B. Results are expressed as per-
centage of the values obtained in the absence of FTA and are given
as mean þ S.D. of the three experiments.
Scheme 1. Farnesylcysteine analogs employed in these studies.
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FTA. The densitometric quantitation of these results appears
in Fig. 2B.
3.3. E¡ect of FTA on the subcellular localization of ras
proteins
It has been reported that certain farnesylated molecules can
interfere with cell growth and impair membrane association of
ras proteins, an important process for ras function [25]. There-
fore, we explored whether FTA induction of apoptosis in HL-
60 cells might be associated with alterations in ras subcellular
localization. Since HL-60 cells contain the oncogene N-ras
[26], we estimated the levels of ras proteins present in S100
or P100 fractions of HL-60 cell extracts by Western blot using
the pan-ras 10 antibody. This antibody recognizes normal ras,
as well as K-, H-, and N-ras [27]. As is shown in Fig. 3A, in
control HL-60 cells, pan-ras-10 immunoreactive proteins
could be detected both in the cytosolic and membrane frac-
tions. Treatment with 10 WM FTA did not reduce the levels of
membrane-associated ras proteins. Interestingly, it brought
about an increase in the proportion of ras proteins present
in the membrane fraction. In contrast to these results, treat-
ment of HL-60 cells with the isoprenoid biosynthesis inhibitor
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Fig. 4. E¡ect of farnesylcysteine analogs on DNA degradation and protein methyltransferase activity. A: HL-60 cells were cultured in the pres-
ence of several farnesylated compounds at 10 WM as indicated. After 12 h cells were harvested and the fragmented DNA was analyzed on agar-
ose gels. STD, 123-bp ladder standard. B: Protein methylation in HL-60 cell extracts was performed by incubation with [3H]SAM in the ab-
sence or presence of the various farnesylcysteine analogs at 50 WM. The autoradiograph shown is representative of three experiments. The
densitometric quantitation of the radioactivity incorporated in the 20^23-kDa group of polypeptides marked in B is shown in C. Results are ex-
pressed as percentage of the values obtained in the absence of analogs and are given as mean þ S.D. of the three experiments.
Fig. 3. E¡ect of FTA on the membrane association of ras proteins. HL-60 cells were incubated in the absence or presence of 10 WM FTA or
10 WM compactin for 8 h. A: The subcellular distribution of ras proteins between membrane (m) and cytosol (c) compartments was analyzed
by immunoblot using a pan-ras antibody. Arrowheads mark the position of the putative unprocessed (upper) and processed (lower) ras pro-
teins. B: The blot shown in A was probed with an anti-calmodulin antibody (CaM, calmodulin). C: The amount of ras present in cells incu-
bated for 8 h in the absence or presence of 10 WM FTA was estimated by Western blot of total cell lysates.
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compactin clearly impaired ras proteins membrane associa-
tion, giving rise to the accumulation of ras in the cytosolic
fraction. This e¡ect probably occurred as a consequence of
impaired isoprenylation, as suggested by the slightly slower
electrophoretic mobility of the immunodetected protein (Fig.
3A). As a control of this experiment blots were re-probed with
an antibody against calmodulin, a predominantly cytosolic
protein. As can be observed in Fig. 3B, neither FTA nor
compactin altered calmodulin subcellular distribution. Finally,
we observed that in total cell lysates from FTA-treated cells,
the levels of ras proteins were not signi¢cantly di¡erent from
those of control cells (Fig. 3C).
3.4. E¡ect of various farnesylcysteine analogs on DNA
degradation and in vitro protein methylation in HL-60 cells
In order to assess the possible importance of PPMTase
inhibition in the induction of apoptosis we studied the e¡ects
of a series of farnesylcysteine analogs (see Scheme 1) of di¡er-
ent potencies as inhibitors of the retinal rod outer segment
PPMTase. Besides FTA, L-AFC and D-AFC [7], we used
farnesoic acid (FA), which is a weak inhibitor of L-AFC
methylation by retinal PPMTase, and the farnesyl phosphate
mono- and dimethyl esters (FPMe and FPMe2, respectively).
These latter analogs are virtually inert both as substrates and
inhibitors of this enzyme (Gilbert et al., unpublished observa-
tions). Incubation of HL-60 cells with the various compounds
at 10 WM for 12 h resulted in loss of cell viability, which
ranged from 20^30% of the cells in all cases, except for FA,
which had no activity. Analysis of cellular DNA showed that
all compounds, except FA, were e¡ective inducers of internu-
cleosomal DNA degradation (Fig. 4A). FTA was the most
potent inducer of DNA laddering. Of the two isomers of
AFC, the D-isomer was slightly more potent. Next, we com-
pared the potency of the various analogs as inhibitors of
PPMTase in HL-60 cell extracts assaying each compound at
50 WM. As shown in Fig. 4B, FTA was the most potent in-
hibitor of in vitro protein methylation. The extent of inhib-
ition attained by the remaining compounds correlated well
with the kinetic constants previously obtained in studies
with the retinal rod outer segment methyltransferase, using
AFC as a substrate [6,7]. FA was ine¡ective as inhibitor of
the methylation of endogenous protein substrates in HL-60
cells and FPMe2 was a poor inhibitor, while L-AFC was
more potent than the D-isomer. The densitometric quantita-
tion of the radioactivity incorporated into the 20^23-kDa
group of polypeptides is given in Fig. 4C.
3.5. E¡ect of farnesylcysteine analogs on ras proteins
subcellular localization
Finally, we explored whether some of these farnesylcysteine
analogs could interfere with ras protein membrane associa-
tion. As is shown in Fig. 5, none of the analogs used impaired
ras membrane association. FA did not alter the partitioning of
ras proteins between the membrane and cytosolic compart-
ments compared to control conditions. However, L-AFC
and, to a somewhat greater extent FPMe2, reduced the pro-
portion of ras-10 immunoreactive proteins in the soluble frac-
tion. However, neither analog was as potent as FTA proved
to be in this regard.
4. Discussion
The results presented here show that the farnesylcysteine
analog FTA is a powerful inhibitor of HL-60 cell growth
and induces apoptosis. A number of farnesylated molecules
share these characteristics of FTA. However, these properties
appear not to correlate with the ability of these molecules to
inhibit the processing of isoprenylated proteins. First, the con-
centrations required to exert the inhibitory activities on cell
growth and survival are lower than those needed to inhibit
protein methylation. Moreover, analogs which are very weak
inhibitors of PPMTase, are e¡ective inducers of apoptosis.
Second, interference of these molecules with the isoprenyla-
tion step is also unlikely, since none of the compounds tested
diminished the electrophoretic mobility or impaired the mem-
brane association of ras proteins. Both e¡ects were observed
when the inhibitor of isoprenoid biosynthesis compactin was
used. These results suggest that isoprenylated molecules can
disrupt signalling pathways through mechanisms not related
to the inhibition of Gp isoprenylation or methylation. It is
likely that the e¡ects of farnesylcysteine analogs arise from
their interaction with intracellular targets capable of recogniz-
ing the isoprenoid moiety.
Recent studies suggest that the modi¢cation of proteins by
isoprenylation and methylation may have important conse-
quences for protein^protein interactions (see [28] and [2] for
reviews). For example, it has been shown that farnesylation of
yeast Ras2 increases its apparent a⁄nity for its e¡ector, ad-
enylyl cyclase, even in the absence of membranes [14]. In
addition, it has recently been reported that isoprenylation of
ras proteins is required for the action of hSOS1, a mammalian
guanine nucleotide exchange factor responsible for activating
ras in response to growth factor stimulation [29]. In the case
of several members of the ras superfamily of small Gp, the
isoprenoid modi¢cation is essential for their interaction with
their respective regulators of guanine nucleotide dissociation,
the GDP dissociation inhibitors rab and rho-GDIs, and the
GDP dissociation stimulator, Smg GDS [17]. The isoprenyla-
tion of heterotrimeric Gp Q-subunits seems important for the
association of K and LQ subunits [15]. In the case of the photo-
receptor Gp, transducin, not only the isoprenylation, but also
the methylation of TQ , contributes to the subunit interaction
between TK and TLQ , thus facilitating the receptor^Gp cou-
pling [30]. The possibility exists that, as has been shown for
rho-GDI [18], some of these proteins may contain domains
which can recognize isoprenyl moieties. This would provide
potential sites of interaction with farnesylated molecules. In
fact, a speci¢c interference of farnesylcysteine analogs with the
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Fig. 5. E¡ect of farnesylcysteine analogs on ras proteins membrane
association. HL-60 cells were incubated in the absence or presence
of the various farnesylated compounds at 10 WM for 8 h. The sub-
cellular distribution of ras proteins between membrane (m) and cy-
tosol (c) compartments was analyzed by immunoblot using the pan-
ras 10 antibody. The position of ras proteins is marked by an ar-
rowhead.
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interaction between activated receptors and Gp has been pre-
viously suggested [31].
It has been previously shown that farnesylcysteine deriva-
tives can inhibit the growth of ras-dependent cell lines [19]. In
the case of the analog farnesylthiosalisylic acid, this e¡ect was
associated with an impairment of ras membrane association
[25]. However, the results reported here clearly show that
isoprenylated molecules can also inhibit cell growth in condi-
tions under which the proportion of membrane-associated ras
proteins is not a¡ected, or is even increased, as in the case of
FTA. Several possibilities could be envisaged that would ex-
plain this observation. Firstly, cytosolic ras or ras-like pro-
teins could be subjected to increased degradation in cells
treated with FTA. However, when total ras levels were moni-
tored by Western blots, no di¡erences could be found between
control and FTA-treated cells. Secondly, farnesylcysteine ana-
logs could interfere with the interaction of ras or ras-like
proteins with a cytosolic acceptor(s). Interestingly, GDIs
and smg-GDS are able to release their cognate small Gp
from membranes, presumably by burying the isoprenylated
moiety in a hydrophobic pocket [32,33], which may be similar
to the structure recently identi¢ed in rho-GDI [18]. It has been
shown previously that various fatty acids and lipids can dis-
rupt the complex of rac protein and rho-GDI, present in the
cytosol of resting human neutrophils [34]. Moreover, it has
been reported that synthetic geranylgeranylated decapeptides,
designed from the carboxyl-terminal region of rap proteins,
can inhibit the interaction of rap proteins with smg-GDS [35].
Finally, a cytosolic acceptor(s) for ras or ras-like proteins
could be subjected to increased degradation in the course of
FTA-induced apoptosis, as has been shown for D4-GDI dur-
ing Fas-induced apoptosis in Jurkat cells [36]. Several of these
possibilities are currently under study.
In conclusion, our results show that several farnesylcysteine
analogs can induce apoptosis in HL-60 cells, and suggest that
the inhibition of PPMTase is not essential for this process. In
the light of recent evidence, our ¢ndings suggest that farne-
sylcysteine analogs could provide a novel approach to explore
the participation of the isoprenyl moieties of signalling pro-
teins in protein^protein interactions.
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